Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999.
D000305:Adrenal Cortex Hormones / Q000009:adverse effects / Q000627:therapeutic use; D003603:Cytotoxins / Q000009:adverse effects / Q000627:therapeutic use; D003937:Diagnosis, Differential; D019317:Evidence-Based Medicine; D006099:Granuloma / Q000188:drug therapy / Q000209:etiology* / Q000473:pathology; D006801:Humans; D008168:Lung / Q000473:pathology; D008171:Lung Diseases / Q000188:drug therapy / Q000209:etiology* / Q000473:pathology; D011379:Prognosis; D012507:Sarcoidosis / Q000188:drug therapy / Q000209:etiology* / Q000473:pathology; D017565:Sarcoidosis, Pulmonary / Q000188:drug therapy / Q000209:etiology* / Q000473:pathology
D000305:Adrenal Cortex Hormones; D003603:Cytotoxins